Gwenn Hansen Sells 4,356 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,356 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00. Following the sale, the insider directly owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. This trade represents a 3.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total value of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Stock Performance

Shares of NRIX traded up $0.43 during mid-day trading on Wednesday, reaching $25.12. The company had a trading volume of 1,343,966 shares, compared to its average volume of 1,507,337. The company’s 50 day simple moving average is $20.80 and its 200 day simple moving average is $17.92. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $25.40. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -7.28 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. As a group, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on NRIX shares. Royal Bank Of Canada upped their price target on shares of Nurix Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Morgan Stanley lifted their price target on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Stifel Nicolaus boosted their price objective on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. HC Wainwright increased their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Jefferies Financial Group raised their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Trending Headlines about Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Sanofi initiated a Phase 1 trial of SAR448272/NX-3911, an oral STAT6 degrader developed through its collaboration with Nurix. The milestone triggered a $10 million payment to Nurix, bringing collaboration proceeds to approximately $139 million. Nurix remains eligible for about $453 million in additional STAT6-related milestones, potential royalties, and retains a U.S. co-development and co-promotion option. Nurix Announces $10 Million Milestone Payment Associated With Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
• Positive Sentiment: Nurix enrolled the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor. The trial is designed to test whether bexobrutideg is superior to pirtobrutinib, advancing the program toward a potential pivotal readout and commercialization. Nurix Announces First Patient Enrolled in Phase 3 DAYBreak CLL-306 Trial
• Positive Sentiment: Needham reaffirmed its Buy rating and assigned a $34 price target, implying substantial upside from the referenced share price. The bullish view reflects confidence in Nurix’s clinical pipeline and upcoming value-creating milestones. Benzinga analyst rating report
• Neutral Sentiment: CFO Hans Van Houte and insider Gwenn Hansen sold shares worth approximately $116,000 and $100,000, respectively. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing the likelihood that the sales signal a change in management’s outlook, although they may add modest near-term selling pressure.

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of NRIX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Nurix Therapeutics by 11.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock valued at $593,000 after purchasing an additional 5,286 shares during the period. Millennium Management LLC boosted its position in shares of Nurix Therapeutics by 106.2% during the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after purchasing an additional 450,262 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Nurix Therapeutics by 9.5% during the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock worth $6,029,000 after purchasing an additional 44,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Nurix Therapeutics by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock worth $1,895,000 after purchasing an additional 12,817 shares during the period. Finally, Creative Planning bought a new stake in Nurix Therapeutics in the second quarter worth approximately $187,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.